Collectively, NNMT’s master regulatory involvement in key metabolic processes in the metabolically active tissues (adipose, liver, and muscle) suggests that NNMT may represent an attractive, druggable target serving as a niche access point to treat obesity and related chronic metabolic diseases. The gene discussed is NNMT; the disease is obesity due to melanocortin 4 receptor deficiency.